Fresh Recalls

Boehringer Ingelheim Pharmaceuticals recalls

Recall found. Boehringer Ingelheim Pharmaceuticals is named in FDA Class II recall D-0657-2026 covering Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets). Hazard: CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product. Identifying details: Lot 3244413; Exp. 12/31/2028. Status: Ongoing.

Models with recalls

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets) (1)

All Boehringer Ingelheim Pharmaceuticals recalls

FDA Class II · Drug · July 8, 2026

Synjardy XR Tablets (empagliflozin and metformin hydrochloride extended-release tablets) recall — Boehringer Ingelheim Pharmaceuticals, Inc.

CGMP Deviations: An incorrect detergent was used and the required swab sampling was not performed on a production hopper that had previously been used for a different product.

Official ID D-0657-2026 · Official record ↗

Verify with the official sources:

Found something wrong or missing? Report a data error.

Compiled from official public-domain government data. Last checked September 7, 2026 at 6:00 AM UTC.